What is mazdutide?
Mazdutide is a long-acting, once-weekly, injectable medicine that is under development for obesity and type 2 diabetes. It is currently undergoing phase 3 clinical trials and is not expected to be submitted for FDA approval until pre-marketing clinical trials have finished, and results have continued to be favorable.
How does mazdutide work?
Mazdutide is a dual glucagon-like peptide 1 receptor agonist (GLP-1RA) and glucagon receptor agonist, the first in its class. By activating both GLP1R and glucagon receptors it helps regulate appetite, metabolism, and improve glucose control. This dual effect appears promising but more clinical trials are needed.
GLP-1 receptors are widely distributed on the beta-cells of the pancreas, brain, and other tissues and are involved in the control of blood sugar levels by enhancing insulin secretion, among other effects. GLP-1 receptor agonists (GLP-1RAs) are already widely used in the treatment of type 2 diabetes because they stimulate insulin synthesis and secretion in a glucose-dependent manner and cause weight loss. They also delay gastric emptying, regulate blood lipid metabolism, reduce fat deposition, and are neuroprotective, anti-infectious, and cardiovascular protective.
Glucagon receptor agonists on their own are not a good therapeutic option because they increase the liver's production of glucose, but if they are combined with GLP-1RAs then they are effective at reducing fat mass and improving glucose tolerance.
What are the side effects of mazdutide?
Clinical trials have so far reported mazdutide to be well tolerated with mild side effects such as:
- upper respiratory tract infection
- diarrhea
- decreased appetite
- nausea
- urinary tract infection
- abdominal distension (bloating)
- vomiting.
How is mazdutide administered?
Mazdutide is administered using a prefilled autoinjector and is given subcutaneously (under the skin), usually in the stomach area, once a week.
Related questions
- Is obesity a major risk factor for Covid-19?
- What is the natural Mounjaro recipe for weight loss?
- Mounjaro vs Ozempic: Which is right for you?
How effective is mazdutide?
Mazdutide is currently undergoing phase 3 clinical trials to assess its effectiveness.
A phase 2 study of 80 adults who received 9mg mazdutide once a week for 24 weeks reported:
- Superior body weight loss with mazdutide with a mean percent change in body weight from baseline versus placebo of -15.4% with a reported treatment difference of 14.7 kg
- Nobody in the placebo group lost 5% or more of their body weight from baseline.
- The authors received funding from Innovent Biologics Inc.
A phase 2 study of 248 participants randomized to receive one of 3 dosing schedules for mazdutide reported:
- An average 7.21% decrease in body weight after 24 weeks. Higher dosages were associated with a higher weight loss (6.35kg on 3mg, 9.07kg on 4.5mg, and 9.85kg on 6mg mazdutide)
- A total of 230 participants (92.7%) completed week 24
- Body-mass index, blood pressure, waist circumference, and liver fat content were all reduced. Lipid levels and insulin sensitivity were improved and transaminase and serum uric acid levels lowered
- The authors received funding from Innovent Biologics Inc.
A phase 1b trial (Ji et al., 2022) of 24 patients (8 received mazdutide 9mg, 8 received mazdutide 10mg, and the rest placebo) reported:
- Those receiving 9mg mazdutide lost an average of 9.8% more weight than those receiving a placebo (an inactive treatment) after 12 weeks
- Those receiving 10mg mazdutide lost an average of 6.2% more weight than those receiving a placebo after 16 weeks
- More profound reductions in waist circumference and BMI were reported with mazdutide
- The authors received funding from Innovent Biologics Inc.
Who makes mazdutide?
Mazdutide is manufactured by Innovent Biologics under a licensing agreement with Eli Lilly and Company (Lilly).
Is mazdutide known by any other name?
Mazdutide is also known as OXM3.
References
- Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., Liu, F., Miller, C., Tota, L. M., Zhou, G., Zhang, X., Sountis, M. M., Santoprete, A., Capito', E., Chicchi, G. G., Thornberry, N., … SinhaRoy, R. (2009). Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes, 58(10), 2258–2266. https://doi.org/10.2337/db09-0278
- Ji, L., Gao, L., Jiang, H., Yang, J., Yu, L., Wen, J., Cai, C., Deng, H., Feng, L., Song, B., Ma, Q., & Qian, L. (2022). Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomized, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinical Medicine, 54, 101691. https://doi.org/10.1016/j.eclinm.2022.101691
- Innovent Announces Phase 2 Study of Mazdutide(IBI362) in Chinese Participants with Overweight or Obesity Met Primary and All Key Secondary Endpoints Cision R Newswire. Jun 07, 2022. https://www.prnewswire.com/news-releases/innovent-announces-phase-2-study-of-mazdutideibi362-in-chinese-participants-with-overweight-or-obesity-met-primary-and-all-key-secondary-endpoints-301562931.html
- Innovent Announces First Participant Dosed in Phase 3 Clinical Study (GLORY-1) of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity. Nov 14, 2022, 19:00 ET Cision PR Newswire https://www.prnewswire.com/news-releases/innovent-announces-first-participant-dosed-in-a-phase-3-clinical-study-glory-1-of-mazdutide-ibi362-in-chinese-adults-with-overweight-or-obesity-301676778.html
- Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., Liu, F., Miller, C., Tota, L. M., Zhou, G., Zhang, X., Sountis, M. M., Santoprete, A., Capito', E., Chicchi, G. G., Thornberry, N., … SinhaRoy, R. (2009). Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes, 58(10), 2258–2266. https://doi.org/10.2337/db09-0278
Read next
Zepbound Vs Mounjaro: Complete Comparison Guide for Weight Loss and Diabetes Treatment
Comprehensive comparison of Zepbound vs Mounjaro. Learn about their uses, dosing, effectiveness, costs, and safety profiles to understand which medication might be right for you. Continue reading
Ozempic Side Effects to Watch For
The most common Ozempic side effects with Ozempic include stomach problems, like nausea, vomiting, diarrhea, stomach pain and constipation. These tend to be mild-to-moderate and usually clear up in a few weeks in most people. Low blood sugar (hypoglycemia) is also a common side effect (when used with certain other diabetes treatments) and it can be serious. Continue reading
Why am I not losing weight on Mounjaro?
It takes time, about 8 to 12 weeks to see a 6% to 8% weight loss in adults using Mounjaro. Other reasons include the need to follow a reduced calorie diet and exercise program, your dose may need to be increased, or side effects may affect your treatment. Continue reading
See also:
Qulipta
Qulipta is used to help prevent episodic or chronic migraine headaches in adults. Qulipta is an ...
Aimovig
Learn about Aimovig (erenumab-aooe) a once-monthly, injectable medication that can be ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Ubrelvy
Ubrelvy (ubrogepant) tablets are used for the acute treatment of migraine. Includes Ubrelvy side ...
Nurtec ODT
Nurtec ODT (rimegepant) is used to treat acute migraines and prevent episodic migraines, by ...
Xeomin
Xeomin (incobotulinumtoxinA) is used to treat cervical dystonia, blepharospasm, upper facial lines ...
Dysport
Dysport (abobotulinumtoxinA) is used to treat cervical dystonia, glabellar lines and limb ...
Botox Cosmetic
Botox Cosmetic is a prescription treatment for fine lines and wrinkles. It temporarily improves the ...
Related medical questions
- How do Ozempic, Mounjaro, Wegovy, Zepbound compare for weight loss?
- Wegovy vs Ozempic: Which is Right for You?
- How long does it take for Ozempic to work?
- How long to see weight loss results with Wegovy?
- Tirzepatide vs semaglutide: How do they compare?
- Does levothyroxine cause weight gain or loss?
- Do Ozempic, Wegovy, Mounjaro & Zepbound cause hair loss?
- Does Wellbutrin XL/SR cause weight gain or loss?
- How does Ozempic work for weight loss?
- Why does Lexapro cause weight gain?
- What happens when you stop taking Ozempic?
- How much is Zepbound with or without insurance?
- Does Lyrica (pregabalin) cause weight gain?
- Does Ozempic need to be refrigerated?
- Saxenda vs Ozempic: For Weight Loss?
- Does gabapentin cause weight gain?
- Does Zoloft (sertraline) cause weight gain?
- Will my insurance cover the cost of Ozempic?
- How does Mounjaro Work for Weight Loss?
- How long does it take for Zepbound to work?
- Does Prozac cause weight gain or loss?
- Can you get tirzepatide from a compounding pharmacy?
- Which GLP-1 drug is best for weight loss?
- Does topiramate cause weight loss?
Related support groups
- Weight Loss (Obesity/Overweight) (858 questions, 1,512 members)
- Diabetes, Type 2 (510 questions, 1,428 members)